Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Farmers Insurance
Accenture
Johnson and Johnson
US Army
Express Scripts

Generated: September 19, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,549,913

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,549,913 protect, and when does it expire?

Patent 9,549,913 protects HETLIOZ and is included in one NDA.

This patent has eighty-four patent family members in twenty-one countries.

Summary for Patent: 9,549,913
Title:Treatment of circadian rhythm disorders
Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Inventor(s): Dressman; Marlene Michelle (Germantown, MD), Licamele; Louis William (Potomac, MD), Polymeropoulos; Mihael H. (Potomac, MD)
Assignee: Vanda Pharmaceuticals, Inc. (Washington, DC)
Application Number:14/374,257
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,549,913
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 9,549,913

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Vanda Pharms Inc HETLIOZ tasimelteon CAPSULE;ORAL 205677-001 Jan 31, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,549,913

PCT Information
PCT FiledJanuary 25, 2013PCT Application Number:PCT/US2013/023315
PCT Publication Date:August 01, 2013PCT Publication Number: WO2013/112951

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Queensland Health
Baxter
Teva
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.